This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Jazz Pharmaceuticals plc
Drug Names(s): SNX-111, ziconotide, omegaconotoxin
Description: Prialt is the first drug in a new class of non-opioid analgesics called N-type calcium channel blockers (NCCBs), administered intrathecally (directly into the fluid surrounding the spinal cord through a surgically implanted catheter), for the treatment of severe chronic pain. Prialt, a synthetic equivalent of a naturally occurring conopeptide found in a marine snail known as Conus magus, selectively blocks calcium channels on the nerves that ordinarily transmit pain signals to the brain.
Elan no longer reports revenues for Prialt as of Q1 2011.
In February 2006, Elan announced that it had agreed to sell the rights to Prialt in Europe to Eisai, while retaining the product rights in the United States. Under the terms of the agreement, Elan may receive up to $100 million in cash; $50 million on the closing of the transaction, a further $10 million on the earlier of two years from closing or launches of Prialt in key European markets, and an additional $40 million contingent on Prialt achieving revenue related milestones in Europe.
In March 2010, Azur Pharma announced it has signed a definitive agreement with Elan Pharmaceuticals to acquire PRIALT. Azur has agreed to acquire worldwide rights (other than Europe) to PRIALT. Financial terms are not disclosed. The acquisition was completed in May 2010.
In September 2011, Jazz Pharmaceuticals and Azur Pharma announced that the companies have agreed to combine in an all-stock transaction. The combined...See full deal structure in Biomedtracker
Partners: Eisai Co., Ltd.
Pink Sheet Chart -- Prialt FDA Reviewers
Pink Sheet Chart -- Prialt Clinical Development
Pink Sheet Elan Prialt pricing
Additional information available to subscribers only: